场景服务
概述
本数据库是全球药物研发领域的权威信息枢纽，致力于提供最全面、最及时的行业洞察，系统收录并整合了覆盖全球范围的药物研发项目全生命周期数据，核心维度包括：适应症（疾病种类）、治疗领域（如肿瘤、神经、免疫等）、研发代码（项目识别号）、研发企业（制药公司、生物技术机构）、作用靶点（分子机制）、研发阶段（从临床前到上市各阶段）以及技术平台（如单抗、小分子、细胞疗法等）。数据库目前已汇聚超过27万条详尽药品研发记录，内容保持即时动态更新。
数据结构及样例
JSON格式
{
"药品名称": "trastuzumab rezetecan",
"中文名称": "瑞康曲妥珠单抗",
"研发代码": [
"SHR-A1811"
],
"创新类型": "创新药",
"改良类型":[""],
"首家研发企业": "江苏恒瑞医药股份有限公司",
"首家研发企业所在地":{"company": {"cn": "江苏恒瑞医药股份有限公司", "en": "Jiangsu Hengrui Medicine Co Ltd"}, "location": {"is_china": "是", "province": "江苏省", "city": "连云港市"}},
"是否国内首家研发企业":"是",
"参与研发的企业":["江苏恒瑞医药股份有限公司"],
"参与研发的企业所在地":[{"company": {"cn": "江苏恒瑞医药股份有限公司", "en": "Jiangsu Hengrui Medicine Co Ltd"}, "location": {"is_china": "是", "province": "江苏省", "city": "连云港市"}}],
"是否国内参与研发企业":["是"],
"剂型": ["冻干粉针剂"],
"给药途径": [
"静脉注射"
],
"active适应症":["转移性非小细胞肺癌"],
"研发状态"：[
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2020-11-10",
"indication": {
"en": "Advanced solid tumor",
"cn": "晚期实体瘤"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2023-10-23",
"indication": {
"en": "Gastroesophageal junction cancer",
"cn": "胃食管连接部癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2023-10-23",
"indication": {
"en": "Transitional cell carcinoma",
"cn": "移行细胞癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2023-10-23",
"indication": {
"en": "Biliary cancer metastatic",
"cn": "转移性胆管癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2023-10-23",
"indication": {
"en": "Colorectal cancer metastatic",
"cn": "转移性结肠直肠癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Australia",
"cn": "澳大利亚"
},
"date": "2023-10-23",
"indication": {
"en": "Metastatic gastric cancer",
"cn": "转移性胃癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2021-09-26",
"indication": {
"en": "Advanced solid tumor",
"cn": "晚期实体瘤"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2023-10-23",
"indication": {
"en": "Gastroesophageal junction cancer",
"cn": "胃食管连接部癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2023-10-23",
"indication": {
"en": "Transitional cell carcinoma",
"cn": "移行细胞癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2023-10-23",
"indication": {
"en": "Biliary cancer metastatic",
"cn": "转移性胆管癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2023-10-23",
"indication": {
"en": "Colorectal cancer metastatic",
"cn": "转移性结肠直肠癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "South Korea",
"cn": "韩国"
},
"date": "2023-10-23",
"indication": {
"en": "Metastatic gastric cancer",
"cn": "转移性胃癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-12-14",
"indication": {
"en": "Biliary cancer",
"cn": "胆道癌"
},
"status": {
"en": "Discovery",
"cn": "药物发现"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2020-09-03",
"indication": {
"en": "Advanced solid tumor",
"cn": "晚期实体瘤"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-10-23",
"indication": {
"en": "Gastroesophageal junction cancer",
"cn": "胃食管连接部癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-10-23",
"indication": {
"en": "Transitional cell carcinoma",
"cn": "移行细胞癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-10-23",
"indication": {
"en": "Biliary cancer metastatic",
"cn": "转移性胆管癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-10-23",
"indication": {
"en": "Colorectal cancer metastatic",
"cn": "转移性结肠直肠癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "US",
"cn": "美国"
},
"date": "2023-10-23",
"indication": {
"en": "Metastatic gastric cancer",
"cn": "转移性胃癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-04-30",
"indication": {
"en": "HER2 low breast cancer",
"cn": "HER2 低表达乳腺癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2022-07-29",
"indication": {
"en": "HER2 positive breast cancer",
"cn": "HER2 阳性乳腺癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-05-17",
"indication": {
"en": "Biliary cancer",
"cn": "胆道癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-09-14",
"indication": {
"en": "Non-small cell lung cancer",
"cn": "非小细胞肺癌"
},
"status": {
"en": "Pre-registration",
"cn": "申请上市"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-02-14",
"indication": {
"en": "Peritoneal neoplasm",
"cn": "腹膜肿瘤"
},
"status": {
"en": "Preclinical",
"cn": "临床前"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-07-10",
"indication": {
"en": "Cervix carcinoma",
"cn": "宫颈癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-07-12",
"indication": {
"en": "Cervix neoplasm",
"cn": "宫颈肿瘤"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-08-23",
"indication": {
"en": "HR+/HER2 low breast cancers",
"cn": "激素受体阳性HER2低表达乳腺癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2020-08-14",
"indication": {
"en": "Colorectal cancer",
"cn": "结肠直肠癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-03-12",
"indication": {
"en": "Ovarian cancer",
"cn": "卵巢癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-02-14",
"indication": {
"en": "Ovarian neoplasm",
"cn": "卵巢肿瘤"
},
"status": {
"en": "Preclinical",
"cn": "临床前"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2022-07-29",
"indication": {
"en": "Breast cancer",
"cn": "乳腺癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-11-20",
"indication": {
"en": "Mammary gland tumour",
"cn": "乳腺肿瘤"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-09-26",
"indication": {
"en": "Solid tumour",
"cn": "实体瘤"
},
"status": {
"en": "Investigational new drug",
"cn": "申报临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-02-14",
"indication": {
"en": "Fallopian tube cancer",
"cn": "输卵管癌"
},
"status": {
"en": "Preclinical",
"cn": "临床前"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2022-04-21",
"indication": {
"en": "Advanced solid tumor",
"cn": "晚期实体瘤"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-06-06",
"indication": {
"en": "Ill-defined disorder",
"cn": "未明确定义的疾病"
},
"status": {
"en": "Investigational new drug",
"cn": "申报临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-01-09",
"indication": {
"en": "Gastroesophageal junction cancer",
"cn": "胃食管连接部癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-03-14",
"indication": {
"en": "Adenocarcinoma",
"cn": "腺癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-10-23",
"indication": {
"en": "Transitional cell carcinoma",
"cn": "移行细胞癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-06-04",
"indication": {
"en": "Biliary cancer metastatic",
"cn": "转移性胆管癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2025-05-27",
"indication": {
"en": "Non-small cell lung cancer metastatic",
"cn": "转移性非小细胞肺癌"
},
"status": {
"en": "Launched",
"cn": "批准上市"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-12-27",
"indication": {
"en": "Colorectal cancer metastatic",
"cn": "转移性结肠直肠癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-07-12",
"indication": {
"en": "Ovarian cancer metastatic",
"cn": "转移性卵巢癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2022-06-16",
"indication": {
"en": "Breast cancer metastatic",
"cn": "转移性乳腺癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-03-14",
"indication": {
"en": "Oesophageal cancer metastatic",
"cn": "转移性食管癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-11-08",
"indication": {
"en": "Metastatic gastric cancer",
"cn": "转移性胃癌"
},
"status": {
"en": "Phase 3 Clinical",
"cn": "Ⅲ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2024-08-09",
"indication": {
"en": "Pancreatic carcinoma metastatic",
"cn": "转移性胰腺癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "China",
"cn": "中国"
},
"date": "2023-07-12",
"indication": {
"en": "Endometrial cancer",
"cn": "子宫内膜癌"
},
"status": {
"en": "Phase 2 Clinical",
"cn": "Ⅱ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2020-09-03",
"indication": {
"en": "Advanced solid tumor",
"cn": "晚期实体瘤"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2023-10-23",
"indication": {
"en": "Gastroesophageal junction cancer",
"cn": "胃食管连接部癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2023-10-23",
"indication": {
"en": "Transitional cell carcinoma",
"cn": "移行细胞癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2023-10-23",
"indication": {
"en": "Biliary cancer metastatic",
"cn": "转移性胆管癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2023-10-23",
"indication": {
"en": "Colorectal cancer metastatic",
"cn": "转移性结肠直肠癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
},
{
"company": {
"en": "Jiangsu Hengrui Medicine Co Ltd",
"cn": "江苏恒瑞医药股份有限公司"
},
"country": {
"en": "Taiwan",
"cn": "中国台湾"
},
"date": "2023-10-23",
"indication": {
"en": "Metastatic gastric cancer",
"cn": "转移性胃癌"
},
"status": {
"en": "Phase 1 Clinical",
"cn": "Ⅰ期临床"
}
}
]
"inactive适应症":[],
"治疗领域": ["肿瘤"],
"靶点": ["HER2", "TOP1"],
"作用机制":["ErbB2酪氨酸激酶受体调节剂","拓扑异构酶1抑制剂"],
"全球最高研发阶段":"批准上市",
"中国最高研发阶段":"批准上市",
"药物类型":["抗体偶联药物","免疫球蛋白G同型抗体","人源化单克隆抗体"],
"工艺技术":["抗体偶联药物", "生物药", "喜树碱", "粉末制剂", "冻干制剂", "免疫球蛋白G同型抗体", "输注", "静脉注射剂", "人源化单克隆抗体"],
"首次获批上市的适应症":["转移性非小细胞肺癌"],
"首次获批上市的国家":["中国"],
"首次获批上市时间":"2025-05-27",
"ATC分类":["抗肿瘤药物和免疫机能调节药物>抗肿瘤药>单克隆抗体和抗体药物偶联物>其他单克隆抗体和抗体药物偶联物"],
"EphMRA分类号":[""],
"化学名称":"",
"分子式":"",
"分子量":"",
"CAS号":"2647845-11-0",
"化学结构":"（示意图地址）",
"专利号":["WO2022068914A1"],
"研发终止时所处阶段":"",
"商品名":[""],
"别名":["trastuzumab rezetecan"],
"研发状态":[{"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2020-11-10", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2023-10-23", "indication": {"cn": "胃食管连接部癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2023-10-23", "indication": {"cn": "移行细胞癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2023-10-23", "indication": {"cn": "转移性胆管癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2023-10-23", "indication": {"cn": "转移性结肠直肠癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "澳大利亚"}, "date": "2023-10-23", "indication": {"cn": "转移性胃癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2021-09-26", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2023-10-23", "indication": {"cn": "胃食管连接部癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2023-10-23", "indication": {"cn": "移行细胞癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2023-10-23", "indication": {"cn": "转移性胆管癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2023-10-23", "indication": {"cn": "转移性结肠直肠癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "韩国"}, "date": "2023-10-23", "indication": {"cn": "转移性胃癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "美国"}, "date": "2023-12-14", "indication": {"cn": "胆道癌"}, "status": {"cn": "药物发现"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "美国"}, "date": "2020-09-03", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "美国"}, "date": "","indication": {"cn":" 晚期实体瘤 "},"status": {"cn":" 临床前 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 美国 "},"date":"2023-10-23","indication": {"cn":" 胃食管连接部癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 美国 "},"date":"2023-10-23","indication": {"cn":" 移行细胞癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 美国 "},"date":"2023-10-23","indication": {"cn":" 转移性胆管癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 美国 "},"date":"2023-10-23","indication": {"cn":" 转移性结肠直肠癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 美国 "},"date":"2023-10-23","indication": {"cn":" 转移性胃癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-04-30","indication": {"cn":"HER2 低表达乳腺癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"", "indication": {"cn": "HER2 阳性乳腺癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2022-07-29", "indication": {"cn": "HER2 阳性乳腺癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2021-12-20", "indication": {"cn": "HER2 阳性乳腺癌"}, "status": {"cn": "临床前"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-05-17", "indication": {"cn": "胆道癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2021-04-14", "indication": {"cn": "非小细胞肺癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-05-22", "indication": {"cn": "非小细胞肺癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "","indication": {"cn":" 非小细胞肺癌 "},"status": {"cn":" 申报临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2024-09-14","indication": {"cn":" 非小细胞肺癌 "},"status": {"cn":" 申请上市 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2025-02-14","indication": {"cn":" 腹膜肿瘤 "},"status": {"cn":" 临床前 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2025-07-10","indication": {"cn":" 宫颈癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-07-12","indication": {"cn":" 宫颈肿瘤 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2024-08-23","indication": {"cn":" 激素受体阳性 HER2 低表达乳腺癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2020-08-14","indication": {"cn":" 结肠直肠癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"", "indication": {"cn": "结肠直肠癌"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-03-07", "indication": {"cn": "卵巢癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-03-12", "indication": {"cn": "卵巢癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-02-14", "indication": {"cn": "卵巢肿瘤"}, "status": {"cn": "临床前"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "","indication": {"cn":" 乳腺癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"", "indication": {"cn": "乳腺癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2022-07-29", "indication": {"cn": "乳腺癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2022-03-11", "indication": {"cn": "乳腺癌"}, "status": {"cn": "临床前"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-04-23", "indication": {"cn": "乳腺肿瘤"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-11-20", "indication": {"cn": "乳腺肿瘤"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2021-12-20", "indication": {"cn": "乳腺肿瘤"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-09-26", "indication": {"cn": "实体瘤"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-02-14", "indication": {"cn": "输卵管癌"}, "status": {"cn": "临床前"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2020-08-13", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2022-04-21", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2020-05-07", "indication": {"cn": "晚期实体瘤"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-06-06", "indication": {"cn": "未明确定义的疾病"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-01-09", "indication": {"cn": "胃食管连接部癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "","indication": {"cn":" 胃食管连接部癌 "},"status": {"cn":" 申报临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2020-08-14","indication": {"cn":" 腺癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-03-14","indication": {"cn":" 腺癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"", "indication": {"cn": "腺癌"}, "status": {"cn": "申报临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-10-23", "indication": {"cn": "移行细胞癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-10-23", "indication": {"cn": "转移性胆管癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-06-04", "indication": {"cn": "转移性胆管癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2021-04-23", "indication": {"cn": "转移性非小细胞肺癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-05-22", "indication": {"cn": "转移性非小细胞肺癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2025-05-27", "indication": {"cn": "转移性非小细胞肺癌"}, "status": {"cn": "批准上市"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2024-09-14", "indication": {"cn": "转移性非小细胞肺癌"}, "status": {"cn": "申请上市"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2021-03-30", "indication": {"cn": "转移性结肠直肠癌"}, "status": {"cn": "Ⅰ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-12-27", "indication": {"cn": "转移性结肠直肠癌"}, "status": {"cn": "Ⅲ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "2023-07-12", "indication": {"cn": "转移性卵巢癌"}, "status": {"cn": "Ⅱ 期临床"}}, {"company": {"cn": "江苏恒瑞医药股份有限公司"}, "country": {"cn": "中国"}, "date": "","indication": {"cn":" 转移性乳腺癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2022-06-16","indication": {"cn":" 转移性乳腺癌 "},"status": {"cn":"Ⅲ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2021-12-20","indication": {"cn":" 转移性乳腺癌 "},"status": {"cn":" 临床前 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2020-08-14","indication": {"cn":" 转移性食管癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-03-14","indication": {"cn":" 转移性食管癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2020-08-14","indication": {"cn":" 转移性胃癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-01-06","indication": {"cn":" 转移性胃癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-11-08","indication": {"cn":" 转移性胃癌 "},"status": {"cn":"Ⅲ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2024-08-09","indication": {"cn":" 转移性胰腺癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国 "},"date":"2023-07-12","indication": {"cn":" 子宫内膜癌 "},"status": {"cn":"Ⅱ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2020-11-10","indication": {"cn":" 晚期实体瘤 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2020-09-03","indication": {"cn":" 晚期实体瘤 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2023-10-23","indication": {"cn":" 胃食管连接部癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2023-10-23","indication": {"cn":" 移行细胞癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2023-10-23","indication": {"cn":" 转移性胆管癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2023-10-23","indication": {"cn":" 转移性结肠直肠癌 "},"status": {"cn":"Ⅰ 期临床 "}}, {"company": {"cn":" 江苏恒瑞医药股份有限公司 "},"country": {"cn":" 中国台湾 "},"date":"2023-10-23","indication": {"cn":" 转移性胃癌 "},"status": {"cn":"Ⅰ 期临床 "}}],
"特殊审批":[],
"全球销售额（百万美元）":[]
}
川公网安备51010702043165
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息